Chennai trail finding is more incidental rather than related to vaccine : AIIMS Director

Vaccine results show no adverse effects, safer for short term usage

New Delhi, Dec 3: The impact of the vaccine during Chennai trial is an incidental finding rather than related to the vaccine candidate, says Dr Randeep Guleria, Director of AIIMS, here today.

“When we vaccinate a large number of people, some of them may have some other disease, which may not be related to the vaccine”, Dr Guleria told ANI.

Talking about the safety of the vaccine, Dr Guleria said that there is data available on the vaccine being safe. He added that around 70,000 to 80,000 volunteers were given the vaccine and they showed no serious adverse effects. The data shows that the vaccine is safer in a short-term period.

Elaborating on the administration of the vaccine to the Indian public, he said, “Hopefully, by the end of this month or early next month, we should get emergency use authorisation from the Indian regulatory authorities to start giving the vaccine to the public.”

The current COVID-19 wave, Guleria says, is on a decline and there can be a big change in the nature of the pandemic if this decline continues for the next three months.

However, there was a halt in the testing and manufacturing of the vaccine when a Chennai-based volunteer alleged to have got serious side effects, including a neurological breakdown, and sought a compensation of Rs 5 crore in a legal notice to the Serum Institute of India. The volunteer was administered the vaccine on October 1 at the Sri Ramachandra Institute of Higher Education and Research, Chennai.

The company called the allegations as “malicious and misconceived” and threatened to seek damages Rs 100 crore.

 

Edited by – Rimjhim Singh

Source – ANI